Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Recruiting · NCT05055908 · Interventional (participants receive a specific treatment) · Lead sponsor: Hunan Province Tumor Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
- Age ≥ 18 years.
- Histologically or cytologically confirmed lung cancer.
- Treated with Immune Checkpoint Inhibitors with or without chemotherapy.
- \. Predicted survival ≥ 12 weeks. 7. Adequate bone marrow hematopoiesis and organ function 8. Presence of measurable lesions according to RECIST 1.1.
Exclusion criteria
- Any conditions can not match for the Inclusion Criteria, includign do not have the data to perform Adverse Events evalutation.
Where it is running
1 location listed.
- Hunan Cancer Hospital - Changsha, Hunan, China